<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02302274</url>
  </required_header>
  <id_info>
    <org_study_id>10-00253</org_study_id>
    <nct_id>NCT02302274</nct_id>
  </id_info>
  <brief_title>Diagnostic Value and Safety of Flecainide Infusion Test in Brugada Syndrome</brief_title>
  <official_title>Diagnostic Value and Safety of Flecainide Infusion Test in Brugada Syndrome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>NYU Langone Health</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>NYU Langone Health</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study aims to use flecainide infusion test as diagnostic test to unmask concealed Brugada&#xD;
      Syndrome cases. It proposes to assess the safety profile of this test in US patients and its&#xD;
      higher sensitivity when compared to procainamide infusion (the conventional drug used in the&#xD;
      USA). As a substudy it proposes to apply this test to early ARVC cases in order to evaluate&#xD;
      if ECG changes similar to those seen in Brugada Syndrome could be unmasked by flecainide iv.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Brugada Syndrome is an inherited arrhythmogenic disease responsible for life-threatening&#xD;
      arrhythmias and sudden cardiac death in young individuals with structural normal heart.&#xD;
&#xD;
      It is characterized by a peculiar ECG pattern, but this pattern could be intermittent. The&#xD;
      infusion of sodium channel blockers (flecainide, ajmaline, procainamide) is used to unmask a&#xD;
      concealed ECG pattern, thus providing an essential contribution to the diagnosis of this&#xD;
      condition.&#xD;
&#xD;
      In the current clinical practice in USA, only procainamide is used for diagnostic purposes;&#xD;
      however in Europe only ajmaline and flecainide, available as iv formulations, are widely&#xD;
      used. European and Japanese studies have demonstrated that the use of flecainide harbors less&#xD;
      risks of adverse events in patients and may have a higher accuracy in unraveling the presence&#xD;
      of the disease.&#xD;
&#xD;
      In the present study the investigators propose to use flecainide infusion test in the&#xD;
      Cardiovascular Genetics Program at NYUMC, in order to assess its sensitivity and specificity&#xD;
      in diagnosing the disease and compare the incidence of adverse events to that observed during&#xD;
      procainamide use.&#xD;
&#xD;
      Additionally, the investigators propose to extend the study protocol to patients with a&#xD;
      suspect diagnosis of Arrhythmogenic Right Ventricular Tachycardia (ARVC), due to the possible&#xD;
      overlap between the two conditions.&#xD;
&#xD;
      The study has the following aims:&#xD;
&#xD;
        1. To demonstrate the higher sensitivity and specificity of flecainide iv infusion compared&#xD;
           to procainamide infusion for the diagnosis of Brugada Syndrome.&#xD;
&#xD;
        2. To demonstrate that flecainide is equally safe or safer than procainamide to use for&#xD;
           diagnosing Brugada Syndrome.&#xD;
&#xD;
        3. To demonstrate that flecainide has high sensitivity and specificity in diagnosing also&#xD;
           some patients with early stage Arrhythmogenic Right Ventricular Cardiomyopathy (ARVC).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 1, 2010</start_date>
  <completion_date type="Actual">July 26, 2017</completion_date>
  <primary_completion_date type="Actual">July 26, 2017</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>diagnosis</measure>
    <time_frame>10 minutes</time_frame>
    <description>conversion from type 2/3 Brugada ECG to diagnostic type 1 ECG</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>absence of arrhythmias elicited during the test</measure>
    <time_frame>10 minutes</time_frame>
    <description>number of arrhythmias caused by</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">209</enrollment>
  <condition>Brugada Syndrome</condition>
  <condition>Arrhythmogenic Right Ventricular Cardiomyopathy</condition>
  <arm_group>
    <arm_group_label>flecainide infusion test</arm_group_label>
    <description>Patients with suspect Brugada Syndrome will be asked to undergo flecainide infusion (2 mg/Kg up to 150 mg maximum dose) over 10 minutes and their ECG will be continuously monitored. The objective of the study is to investigate if they show conversion from type 2 or type 3 ECG to a diagnostic type 1 ECG.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>flecainide iv</intervention_name>
    <description>infusion over 10 min</description>
    <arm_group_label>flecainide infusion test</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        All adult patients (age&gt;18) who are seen in the Cardiovascular Genetics Program with a&#xD;
        suspect diagnosis of Brugada Syndrome or with a suspect diagnosis of ARVC. This study will&#xD;
        enroll adult individuals who are referred to the Center with a suspect of Brugada Syndrome&#xD;
        or ARVC on the basis of uncertain ECG pattern, family history for sudden death syncope&#xD;
        and/or cardiac arrest and/or ventricular arrhythmia in the absence of clear clinical&#xD;
        markers for any other inherited cardiac disease.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Suspect diagnosis of Brugada Syndrome or ARVC&#xD;
&#xD;
          -  Idiopathic ventricular fibrillation and suspect concealed Brugada syndrome&#xD;
&#xD;
          -  Family history of Brugada Syndrome&#xD;
&#xD;
          -  Family history of unexpected cardiac sudden death&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Type 1 Brugada Syndrome ECG&#xD;
&#xD;
          -  Pregnancy&#xD;
&#xD;
          -  History and/or evidence of ischemic cardiomyopathy&#xD;
&#xD;
          -  Recent myocardial infarction&#xD;
&#xD;
          -  Allergy or known adverse reaction to flecainide&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Steven Fowler, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>NYU School of Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>New york University, School of Medicine</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10010</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2019</verification_date>
  <study_first_submitted>November 24, 2014</study_first_submitted>
  <study_first_submitted_qc>November 25, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 26, 2014</study_first_posted>
  <last_update_submitted>April 16, 2019</last_update_submitted>
  <last_update_submitted_qc>April 16, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">April 18, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Brugada Syndrome</keyword>
  <keyword>ARVC</keyword>
  <keyword>flecainide</keyword>
  <keyword>ST elevation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cardiomyopathies</mesh_term>
    <mesh_term>Brugada Syndrome</mesh_term>
    <mesh_term>Arrhythmogenic Right Ventricular Dysplasia</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Flecainide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

